Literature DB >> 31821460

A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation.

Li Li1,2, Han Chen3, David Marin1, Yuanxin Xi3, Qi Miao3, Jiangxing Lv1, Pinaki Prosad Banerjee1, Hila Shaim1, May Daher1, Rafet Basar1, Nobuhiko Imahashi1, Juan Jimenez1, Bingqian Hu1, Rohtesh S Mehta1, Lucila Nassif Kerbauy1, Mecit Kaplan1, Mayela Mendt1, Gonca Ozcan1, Elif Gokdemir1, Mayra Hernandez Sanabria1, Ye Li1, Ken Chen3, Jing Wang3, Luis Muniz-Feliciano1, Wei-Li Zhao2, Richard E Champlin1, Elizabeth J Shpall1, Katayoun Rezvani1.   

Abstract

Natural killer (NK) cells are highly heterogeneous, with vast phenotypic and functional diversity at the single-cell level. They are involved in the innate immune response against malignant and virus-infected cells. To understand the effect of NK diversity during immune recovery on the antitumor response after cord blood transplantation (CBT), we used high-dimensional mass cytometry and the metrics of NK cell diversity to study the NK cell repertoire in serial samples from 43 CBT recipients. A higher-diversity index based on single-cell combinatorial phenotypes was significantly associated with a lower risk for relapse after CBT (P = .005). Cytomegalovirus reactivation was a major factor in the development of a more diverse NK repertoire after CBT. Notably, we identified a group of patients whose CB-derived NK cells after transplantation possessed an immature phenotype (CB-NKim), characterized by poor effector function and a low diversity index. Frequencies of CB-NKim of 11.8% or higher during the early post-CBT recovery phase were highly predictive for relapse (area under the curve [AUC], 0.979), a finding that was validated in a second independent cohort of patients (n = 25; AUC, 0.977). Moreover, we showed that the maturation, diversity, and acquisition of effector function by CB-NKim early after CBT were driven by interleukin 15. Our data indicate that the diversity of the NK cell repertoire after CBT contributes importantly to the risk for subsequent relapse. We suggest that the use of diversity metrics and high-dimensional mass cytometry may be useful tools in predicting clinical outcomes and informing the design of therapeutic strategies to prevent relapse after CBT.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 31821460      PMCID: PMC6963241          DOI: 10.1182/bloodadvances.2019000835

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  48 in total

1.  Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/- umbilical cord blood.

Authors:  Mariella Della Chiesa; Michela Falco; Alice Bertaina; Letizia Muccio; Claudia Alicata; Francesco Frassoni; Franco Locatelli; Lorenzo Moretta; Alessandro Moretta
Journal:  J Immunol       Date:  2014-01-17       Impact factor: 5.422

2.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

Authors:  Loredana Ruggeri; Antonella Mancusi; Marusca Capanni; Elena Urbani; Alessandra Carotti; Teresa Aloisi; Martin Stern; Daniela Pende; Katia Perruccio; Emanuela Burchielli; Fabiana Topini; Erika Bianchi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

3.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  Bipin N Savani; Katayoun Rezvani; Stephan Mielke; Aldemar Montero; Roger Kurlander; Charles S Carter; Susan Leitman; Elizabeth J Read; Richard Childs; A John Barrett
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

4.  Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory.

Authors:  Travis A Doering; Alison Crawford; Jill M Angelosanto; Michael A Paley; Carly G Ziegler; E John Wherry
Journal:  Immunity       Date:  2012-11-15       Impact factor: 31.745

5.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Philip B McGlave; Jeffrey S Miller; Catherine M Verfaillie; John E Wagner
Journal:  Blood       Date:  2004-10-05       Impact factor: 22.113

6.  Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma.

Authors:  Michael Koldehoff; Stefan R Ross; Ulrich Dührsen; Dietrich W Beelen; Ahmet H Elmaagacli
Journal:  Leuk Lymphoma       Date:  2016-08-10

7.  NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.

Authors:  Antonio Russo; Giacomo Oliveira; Sofia Berglund; Raffaella Greco; Valentina Gambacorta; Nicoletta Cieri; Cristina Toffalori; Laura Zito; Francesca Lorentino; Simona Piemontese; Mara Morelli; Fabio Giglio; Andrea Assanelli; Maria Teresa Lupo Stanghellini; Chiara Bonini; Jacopo Peccatori; Fabio Ciceri; Leo Luznik; Luca Vago
Journal:  Blood       Date:  2017-10-06       Impact factor: 22.113

8.  The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.

Authors:  R H Rouce; H Shaim; T Sekine; G Weber; B Ballard; S Ku; C Barese; V Murali; M-F Wu; H Liu; E J Shpall; C M Bollard; K R Rabin; K Rezvani
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

Review 9.  NK Cell Exhaustion.

Authors:  Jiacheng Bi; Zhigang Tian
Journal:  Front Immunol       Date:  2017-06-28       Impact factor: 7.561

10.  PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.

Authors:  Asma Beldi-Ferchiou; Marion Lambert; Stéphanie Dogniaux; Frédéric Vély; Eric Vivier; Daniel Olive; Stéphanie Dupuy; Frank Levasseur; David Zucman; Céleste Lebbé; Damien Sène; Claire Hivroz; Sophie Caillat-Zucman
Journal:  Oncotarget       Date:  2016-11-08
View more
  11 in total

1.  Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation.

Authors:  Hisayuki Yokoyama; Junya Kanda; Yuta Kawahara; Naoyuki Uchida; Masatsugu Tanaka; Satoshi Takahashi; Makoto Onizuka; Yuma Noguchi; Yukiyasu Ozawa; Yuna Katsuoka; Shuichi Ota; Takanori Ohta; Takafumi Kimura; Yoshinobu Kanda; Tatsuo Ichinohe; Yoshiko Atsuta; Hideki Nakasone; Satoko Morishima
Journal:  Bone Marrow Transplant       Date:  2021-01-08       Impact factor: 5.483

2.  Next-generation cell therapies: the emerging role of CAR-NK cells.

Authors:  Rafet Basar; May Daher; Katayoun Rezvani
Journal:  Blood Adv       Date:  2020-11-24

Review 3.  Next-generation cell therapies: the emerging role of CAR-NK cells.

Authors:  Rafet Basar; May Daher; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.

Authors:  Ye Li; Rafet Basar; Guohui Wang; Enli Liu; Judy S Moyes; Li Li; Lucila N Kerbauy; Nadima Uprety; Mohsen Fathi; Ali Rezvan; Pinaki P Banerjee; Luis Muniz-Feliciano; Tamara J Laskowski; Emily Ensley; May Daher; Mayra Shanley; Mayela Mendt; Sunil Acharya; Bin Liu; Alexander Biederstädt; Hind Rafei; Xingliang Guo; Luciana Melo Garcia; Paul Lin; Sonny Ang; David Marin; Ken Chen; Laura Bover; Richard E Champlin; Navin Varadarajan; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Nat Med       Date:  2022-09-29       Impact factor: 87.241

5.  T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.

Authors:  Laura T Morton; Tassilo L A Wachsmann; Miranda H Meeuwsen; Anne K Wouters; Dennis F G Remst; Marleen M van Loenen; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

6.  Immunoprofiling reveals cell subsets associated with the trajectory of cytomegalovirus reactivation post stem cell transplantation.

Authors:  Lauren Stern; Helen M McGuire; Selmir Avdic; Barbara Fazekas de St Groth; David Gottlieb; Allison Abendroth; Emily Blyth; Barry Slobedman
Journal:  Nat Commun       Date:  2022-05-11       Impact factor: 17.694

7.  Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.

Authors:  Lucila N Kerbauy; Nancy D Marin; Mecit Kaplan; Pinaki P Banerjee; Melissa M Berrien-Elliott; Michelle Becker-Hapak; Rafet Basar; Mark Foster; Luciana Garcia Melo; Carly C Neal; Ethan McClain; May Daher; Ana Karen Nunez Cortes; Sweta Desai; Francesca Wei Inng Lim; Mayela Carolina Mendt; Timothy Schappe; Li Li; Hila Shaim; Mayra Shanley; Emily L Ensley; Nadima Uprety; Pamela Wong; Enli Liu; Sonny O Ang; Rong Cai; Vandana Nandivada; Vakul Mohanty; Qi Miao; Yifei Shen; Natalia Baran; Natalie W Fowlkes; Ken Chen; Luis Muniz-Feliciano; Richard E Champlin; Yago L Nieto; Joachim Koch; Martin Treder; Wolfgang Fischer; Oswaldo Keith Okamoto; Elizabeth J Shpall; Todd A Fehniger; Katayoun Rezvani
Journal:  Clin Cancer Res       Date:  2021-05-13       Impact factor: 13.801

8.  Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.

Authors:  May Daher; Rafet Basar; Elif Gokdemir; Natalia Baran; Nadima Uprety; Ana Karen Nunez Cortes; Mayela Mendt; Lucila Nassif Kerbauy; Pinaki P Banerjee; Mayra Shanley; Nobuhiko Imahashi; Li Li; Francesca Lorraine Wei Inng Lim; Mohsen Fathi; Ali Rezvan; Vakul Mohanty; Yifei Shen; Hila Shaim; Junjun Lu; Gonca Ozcan; Emily Ensley; Mecit Kaplan; Vandana Nandivada; Mustafa Bdiwi; Sunil Acharya; Yuanxin Xi; Xinhai Wan; Duncan Mak; Enli Liu; Xin Ru Jiang; Sonny Ang; Luis Muniz-Feliciano; Ye Li; Jing Wang; Shahram Kordasti; Nedyalko Petrov; Navin Varadarajan; David Marin; Lorenzo Brunetti; Richard J Skinner; Shangrong Lyu; Leiser Silva; Rolf Turk; Mollie S Schubert; Garrett R Rettig; Matthew S McNeill; Gavin Kurgan; Mark A Behlke; Heng Li; Natalie W Fowlkes; Ken Chen; Marina Konopleva; Richard E Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2021-02-04       Impact factor: 25.476

9.  GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.

Authors:  Enli Liu; Sonny O T Ang; Lucila Kerbauy; Rafet Basar; Indreshpal Kaur; Mecit Kaplan; Li Li; Yijiu Tong; May Daher; Emily L Ensley; Nadima Uprety; Ana Karen Nunez Cortes; Ryan Z Yang; Ye Li; Hila Shaim; Francia Reyes Silva; Paul Lin; Vakul Mohanty; Sunil Acharya; Mayra Shanley; Luis Muniz-Feliciano; Pinaki P Banerjee; Ken Chen; Richard E Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 8.786

Review 10.  Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment.

Authors:  Ane Orrantia; Iñigo Terrén; Gabirel Astarloa-Pando; Olatz Zenarruzabeitia; Francisco Borrego
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.